Welcome to PsychU!

Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia. Objectives:

  • Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
  • Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
  • Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
 

References

  1. Dedic N, et al. Int J Mol Sci. 2021;22(24):13185. doi:10.3390/ijms222413185
  2. Nair PC, et al. Mol Psychiatry. August 10, 2021. doi:10.1038/s41380-021-01250-7

Featuring

Christoph-Correll

Christoph Correll, MD

Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

More
Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.
Jehan-Marino

Jehan Marino, PharmD, BCPP (OPDC)

Clinical & Scientific Director

Speaker Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Jehan Marino, PharmD, BCPP is an employee for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Log in to register

Related Resources